Gene Therapy Financial Exposure
A single gene therapy claim can cost $2–4 million — potentially exceeding the entire annual claims budget for a small employer. For a 500-employee self-funded plan with a $5 million annual claims budget, a single gene therapy claim would represent 40–80% of annual claims. The financial impact is catastrophic without adequate stop-loss protection.
Probability of Exposure
| Condition | Prevalence | Probability in 500-Employee Plan |
|---|---|---|
| Hemophilia B | 1 in 30,000 | ~2% per year |
| Sickle cell disease | 1 in 365 (African Americans) | Variable by demographics |
| Beta-thalassemia | 1 in 100,000 | <1% per year |
| Duchenne MD (pipeline) | 1 in 3,500 males | ~1% per year |
Stop-Loss Protection
Watch Out
Many stop-loss carriers are excluding gene therapies from coverage — or adding specific lasers for members with gene therapy-eligible conditions. Review your stop-loss contract carefully for gene therapy exclusions. If your stop-loss contract excludes gene therapies, you have unlimited financial exposure for these claims. Work with your stop-loss broker to find coverage that includes gene therapies.